At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LBPH Longboard Pharmaceuticals, Inc.
Market Closed 11-15 16:00:00 EST
59.69
-0.05
-0.08%
盘后59.69
+0.000.00%
17:05 EST
High59.83Low59.47Vol1.22M
Open59.76D1 Closing59.74Amplitude0.60%
Mkt Cap2.33BTradable Cap1.49BTotal Shares39.05M
T/O72.74MT/O Rate4.88%Tradable Shares24.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
TIPRANKS  ·  11-13
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
BRIEF-Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Reuters  ·  11-12
BRIEF-Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Initiates Phase 3 Deep Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (Dees)
THOMSON REUTERS  ·  11-12
Longboard Pharmaceuticals Initiates Phase 3 Deep Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (Dees)
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Business Wire  ·  11-12
Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals (LBPH) Receives a Hold from Truist Financial
TIPRANKS  ·  11-11
Longboard Pharmaceuticals (LBPH) Receives a Hold from Truist Financial
Longboard Pharmaceuticals Advances Neurological Treatments
TIPRANKS  ·  11-09
Longboard Pharmaceuticals Advances Neurological Treatments
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
reuters  ·  11-08
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Longboard Pharmaceuticals Q3 2024 GAAP EPS $(0.63) Misses $(0.57) Estimate
Benzinga  ·  11-08
Longboard Pharmaceuticals Q3 2024 GAAP EPS $(0.63) Misses $(0.57) Estimate
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
THOMSON REUTERS  ·  11-08
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Business Wire  ·  11-08
Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin
TIPRANKS  ·  11-05
Longboard Pharmaceuticals granted Orphan Drug Designation for bexicaserin
Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings
TIPRANKS  ·  11-01
Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings
HC Wainwright Downgrades Longboard Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $60 From $80
MT Newswires Live  ·  10-16
HC Wainwright Downgrades Longboard Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $60 From $80
Longboard Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
TIPRANKS  ·  10-15
Longboard Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
Strong Valuation and Strategic Acquisition Drive Buy Rating for Longboard Pharmaceuticals
TIPRANKS  ·  10-15
Strong Valuation and Strategic Acquisition Drive Buy Rating for Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc : H.c. Wainwright Cuts to Neutral From Buy; Cuts Target Price to $60 From $80
THOMSON REUTERS  ·  10-15
Longboard Pharmaceuticals Inc : H.c. Wainwright Cuts to Neutral From Buy; Cuts Target Price to $60 From $80
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
Zacks  ·  10-15
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
BRIEF-Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
Reuters  ·  10-15
BRIEF-Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion
TIPRANKS  ·  10-15
Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion
Longboard Pharmaceuticals: IF Deal Is Terminated Under Some Circumstances, Co Required to Pay H. Lundbeck a/S Termination Fee of $86.1 Mln
THOMSON REUTERS  ·  10-15
Longboard Pharmaceuticals: IF Deal Is Terminated Under Some Circumstances, Co Required to Pay H. Lundbeck a/S Termination Fee of $86.1 Mln
No data available

Introduction

Company Name.
Longboard Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Issue price:
--